Major Announcement! Huajian Medical and BizHealth Enter the 'Practical Implementation Phase' of AI Healthcare

At the start of 2026, competition in the global AI healthcare sector was fierce. True game-changers, however, never play by the book. In just 72 hours, Huajian Medical (01931.HK) delivered a lightning-fast 'one-two punch' to the entire market, signaling that its AI healthcare ecosystem integration has moved beyond theoretical discussions into the practical harvesting phase.

First move: Full green light from policy.On January 12, the State Administration for Market Regulation issued an approval document stating that it would not conduct further antitrust reviews on Huajian Medical's acquisition of equity in Chuangye Hui Kang (300451.SZ), clearing a key policy hurdle for deep integration.

Second move: Business synergy takes off.On January 14, senior executives from both parties gathered at Chuangye Hui Kang Tower for the first business cooperation exchange meeting, marking a substantial leap from financial investment to business integration.

Third move: Building market confidence.On the same day, following the company’s repurchase of over HKD 100 million worth of shares in 2025, Huajian Medical initiated a new round of share buybacks, demonstrating its firm belief in its own value and strategic prospects with real capital. The market responded quickly, with the company's stock closing higher for two consecutive days.

This is not a random accumulation of favorable factors, but a clear signal from Huajian Medical to the market: our AI healthcare story is a closed loop, can be implemented, and we are willing to take full responsibility.

At the meeting, core management members such as Mr. He Jucheng, founder of Huajian Medical and CEO of Wistar Medical, Mr. Liang Jingxin, founder of Huajian Medical, and Mr. Lin Xianya, Executive Director of Huajian Medical and General Manager of Dacheng Medical, were present alongside key figures from Chuangye Huikang, including Chairman Zhang Lüzhen, President Chen Zhongyang, and Executive President Chen Dong, to discuss plans for synergistic development.

The meeting focused on efficiently advancing 'integration empowerment,' from product interpretation to detailed collaboration pathways, with the clear goal of transforming synergy into tangible financial results.

Mr. Zhang Lvzhen, Chairman of Chuangye HuikangIn his opening remarks, he pointed out that there is a high overlap between the two parties' clients and decision-making chains, emphasizing that synergy lies in resource sharing and pathway reuse, which can significantly reduce costs and improve efficiency.

Mr. Lin Xianya, Executive Director of Huajian MedicalHe emphasized that the combination of these two companies, each with over 30 years of history, aims to 'further expand business together' amid economic pressures, with the high compatibility of their DNA serving as the foundation for synergy.

Mr. He Jucheng, the founder of Huajian MedicalHe further elevated the strategic intent of synergy by highlighting that Huajian Medical serves over 3,000 hospitals while Chuangye Huikang covers more than 10,000 institutions. Their combination will 'definitely result in 1+1>2,' aiming to solidify the performance foundation for the coming years through channel and customer chemistry.

Mr. Chen Zhongyang, President of Chuangye HuikangHe noted that synergy is not only happening on the market side but also presents significant win-win opportunities in product development, service delivery, and even at the technological level in the future.

This meeting sent an extremely clear signal: synergy has entered the 'granular' stage. What Huajian seeks is not just consolidated profits, but the unique commercialization speed and data barriers brought by Chuanzhi Hui Kang’s underlying network. This strategic move allows it to leap from the fierce 'algorithm competition' to the contest for 'ecosystem control.'

The true core of the meeting lies in the implementation of business synergy mechanisms. What Huajian Medical brings to Chuanzhi Hui Kang goes beyond capital—it provides a 'three-stage rocket' propulsion system that can rapidly amplify the value of its data assets and technical products.

First, there is the 'multiplier effect' of the channel network.Huajian Medical's IVD distribution network, built through its subsidiary Wensida, is one of its deepest moats in the medical field.

Since becoming the exclusive partner for Sysmex’s coagulation products in China in 1997, this network has installed over 6,600 coagulation analyzers, covering all 31 provinces/municipalities/autonomous regions in China, with 1,073 distribution nodes, ultimately reaching more than 1,700 tertiary hospitals nationwide.

For Chuanzhi Hui Kang, this means that its HI-HIS system, smart hospital solutions, and even APTS and other AI products now have a 'highway' directly accessing China’s top medical institutions.

Next is the 'chemical reaction' within the data ecosystem.The 300 million resident health records and 100 million electronic medical records accumulated by Chuanzhi Hui Kang serve as the most precious 'fuel' for training large-scale vertical models in healthcare.

After integrating into the 'Huajian Ecosystem,' these high-quality structured data will synergize with the technical capabilities of over 20 IVD companies within the ecosystem covering fields such as POCT, mass spectrometry, and molecular diagnostics. This synergy will give rise to integrated hardware-software solutions like 'intelligent diagnostic all-in-one machines,' achieving exponential growth in both customer value and loyalty.

Finally, there is the 'value discovery' in capital operations.This represents Huajian Medical's most differentiated core competency. The company plans to use innovative financial tools such as professional intellectual property securitization to open up new value realization pathways for AI products under Chuangye Hui Kang that have already been clinically validated (such as the APTS model).

This fundamentally changes the valuation logic of high-tech medical assets, shifting from a pure profit discount model to an upfront pricing of future knowledge-based cash flows.

The synergy between the two parties comes just before the explosion of the AI healthcare industry. The year 2026 is widely recognized as the 'golden year of AI healthcare explosion,' where policy, market, and technology form a powerful triad driving the industry into a phase of rapid development.

At the policy level, the 'Implementation Opinions on Promoting and Regulating the Application Development of Artificial Intelligence + Healthcare' sets phased development goals for 2027 and 2030, adhering to the fundamental principle of empowering rather than replacing through artificial intelligence.

In terms of the market, according to Grand View Research, the global AI healthcare market size was approximately $26.65 billion (approximately RMB 186.1 billion) in 2024 and is expected to soar to about $505.59 billion (approximately RMB 3.5 trillion) by 2033, with a compound annual growth rate of 38.8% during this period.

Meanwhile, the competitive landscape of the global AI healthcare field is already heating up. OpenAI has launched its first AI healthcare product, ChatGPT HealthAI, while Anthropic, the trillion-dollar AI unicorn, unveiled its new model, Claude for Healthcare. Elon Musk’s brain-computer interface has ignited the neuro-medical field, and NVIDIA has partnered with Eli Lilly and Co to build the strongest AI pharmaceuticals lab. Domestically, Ant Group’s Afu has sparked the AI healthcare race, with tech giants like Alibaba, JD.com, and Huawei all heavily entering the fray, marking the beginning of a 'tough battle' in AI healthcare.

In such a competitive landscape, why is Huajian Medical so confident in investing in the future? The answer lies in the company's unique business model and differentiated strategy.

Unlike other companies betting on a single technology or product, Huajian Healthcare has chosen mergers and acquisitions (M&A) integration as its sole approach to building a 'capital-industry-data' gravitational field, enabling any outstanding AI medical technology to be commercialized rapidly. The successful acquisition and synergy launch of Chuanzhi Healthcare marks a key move in this strategy. Starting from this point, Huajian Healthcare will continue to screen"High-Tech, Globalization, Large Assets"targets that meet thestandards, focusing on core areas such as primary-level intelligent diagnosis and treatment, large-scale medical models, digital therapeutics, AI-driven drug discovery, and chronic disease management.，to build an AI healthcare industry community.

Supporting this strategy is Huajian Healthcare's three-curve comprehensive empowerment system: The K1 curve’s IVD distribution network provides scenario entry points and channel support, the K2 curve’s ecosystem enables technological synergy and resource integration, while the K3 curve’s capital operation capabilities accelerate value realization and R&D iteration.

Meanwhile, Huajian Healthcare’s global capital layout supplies ample 'ammunition' for this strategy—Huajian Healthcare is already listed on the Hong Kong Stock Exchange, with preparations for dual listing on the US stock market (filing submitted) proceeding steadily, forming a global financing system that offers robust funding guarantees for ongoing M&A integration and ecosystem expansion.

The acquisition of Chuanzhi Healthcare and the initiation of deep synergy represent a pivotal chapter in Huajian Healthcare’s grand strategy. It validates the feasibility and power of its 'M&A-integration-empowerment' model and demonstrates our determination to build an AI healthcare ecosystem community.

The ultimate vision goes far beyond mere commercial success. The company aims to promote universal access to high-quality healthcare through M&A integration, addressing humanity’s most pressing issues today—diseases, aging, and healthcare inequality—ultimately allowing billions to 'live better.' Standing at the forefront of 2026, Huajian Healthcare is accelerating toward a more inclusive, precise, and efficient future in healthcare, breaking down geographic, economic, and technological barriers to bring quality medical resources to broader populations.